How do you think ZIOP's STS trial results due in a couple of weeks will affect THLD's price?
If positive, will THLD go down, due to successful competition?
If negative, will THLD go up? Or could THLD go down instead, if it puts doubts in people's minds about adjuntive alkylating agents in STS, which would include TH-302 also? (albeit ours, unlike ZIOP's drug, is specialized for hypoxia).
Any thoughts? Thanks
There is no comparison. TH-302 is more effacious hands down. Less toxic as well. The comparisons have been thrown on this board more than once. Check out both websites and see for yourself. Unless you have other motives for your question
With the conference out of the way....whats the next event that can take us over 5 ? Seems like low 5s are a big resistance to overcome....Hope we can bust through that, so it can rumble over the shorts.